---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018793"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:29:40.688838+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ensysce Biosciences reports Q1 net loss of $3.1M; advances PF614 Phase 3 plans

## Summary
- Net loss attributable to common stockholders was $3.1M for Q1 2024, vs $2.2M in Q1 2023.
- Cash increased to $3.4M at March 31, 2024 from $1.1M at Dec 31, 2023, boosted by $6.8M in warrant exercises.
- R&D expenses decreased to $0.8M from $1.8M YoY; G&A decreased to $1.4M from $1.6M.
- FDA granted Breakthrough Therapy designation for PF614-MPAR in January; Phase 3 trial for PF614 expected to start H2 2024.
- Federal grant revenue fell to $0.3M from $0.8M due to completion of MPAR grant in Dec 2023.

## SEC filing metadata
- accession: 0001493152-24-018793
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315224018793/0001493152-24-018793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315224018793/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018793
- JSON: https://secwatch.observer/filing/0001493152-24-018793.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018793.txt

## Key facts
- Earnings Releases
  Ensysce Biosciences, Inc. reported first quarter ended March 31, 2024 results: net income $3.1 million.
  - Period: first quarter ended March 31, 2024
  - Net income: $3.1 million
  - Result: reported results
  source text: On May 13, 2024, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315224018793/0001493152-24-018793-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.